CDEC

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Itch, Medication, Alagille syndrome, Liver disease, Inflammation, Patient, Cholestasis, Bile, Cholestatic pruritus, CADTH, Liver injury, The Hospital, Liver, CDEC, Genetic disorder, PFIC, Pharmaceutical industry

“The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.

Key Points: 
  • “The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.
  • These patients suffer greatly from the debilitating and disruptive effects of Alagille syndrome, which often starts in early childhood.”
    “CADTH’s recommendation of reimbursement for LIVMARLI provides a meaningful advancement in the treatment of cholestatic pruritus for patients with Alagille syndrome.
  • LIVMARLI is also approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. and Europe, and for Progressive Familial Intrahepatic Cholestasis (PFIC) in the U.S. and in Europe.
  • Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.

Early Educator Investment Collaborative Makes $9 Million in Grants to Address Unjust Compensation for Early Childhood Education Workforce

Retrieved on: 
Wednesday, November 15, 2023
Woman, OSSE, Policy, Organization, Workforce, Learning, State, Implement, Student, Occupation, Data collection, Plague, Data, Knowledge, CDEC, Parity, Magnetic resonance, Education, Nursing, Tutoring, Risk management, Toy, Collaboration, ECE

WASHINGTON, Nov. 15, 2023 /PRNewswire/ -- Today the Early Educator Investment Collaborative (The Collaborative) awarded $9M in grants to support public systems innovations in increasing wages and benefits for the early childhood education (ECE) workforce. Colorado Department of Early Childhood, the District of Columbia Office of the State Superintendent of Education, and Louisiana Policy Institute for Children will work with state and local partners to explore unique approaches to boost early educator compensation.

Key Points: 
  • WASHINGTON, Nov. 15, 2023 /PRNewswire/ -- Today the Early Educator Investment Collaborative (The Collaborative) awarded $9M in grants to support public systems innovations in increasing wages and benefits for the early childhood education (ECE) workforce.
  • "These grants support state and local government agencies working to implement durable, sustainable ways to raise early educator compensation, which we know leads directly to better learning outcomes for children."
  • Inadequate compensation and benefits continue to plague the ECE workforce, with compensation for early educators remaining low and far behind other occupations with similar credentials.
  • Created in 2017, the Early Educator Investment Collaborative aims to accelerate progress in the early childhood education profession and ensure early educators have the supports they need to be well-prepared and appropriately compensated.

Origis Energy Announces Construction on 200 MW Escalante Solar

Retrieved on: 
Wednesday, August 30, 2023
Climate Change and Energy Transition Act, Tri-State Transportation Campaign, CDEC, Pacific Coast Electric Transmission Association, School district, Energy transition, Coal, Gravenstein Union School District, Citizens for Responsible Energy Solutions, County, Highley, Renewable energy, Escalante Solar Project

GRANTS, N.M., Aug. 30, 2023 /PRNewswire/ -- Origis Energy today announced construction has begun on the Escalante Solar Project near Grants, N.M. The 200-megawatt solar project is at the site of the decommissioned Escalante Station, a 253-megawatt coal-powered plant that Tri-State closed in 2020. Tri-State Generation and Transmission Association has entered into a power purchase agreement for the output of generation from the Escalante Solar Project.

Key Points: 
  • GRANTS, N.M., Aug. 30, 2023 /PRNewswire/ -- Origis Energy today announced construction has begun on the Escalante Solar Project near Grants, N.M.
  • Tri-State Generation and Transmission Association has entered into a power purchase agreement for the output of generation from the Escalante Solar Project.
  • "We are excited to help create a milestone for Tri-State in their renewable energy goals," said Tanya Sessions, vice president, business development of Origis Energy.
  • Origis Energy, one of America's leading renewable energy platforms, acquired the development rights for the Escalante Solar Project from TurningPoint Energy, which originally developed the project.

MYEG COLLABORATES WITH PHILIPPINES BUREAU OF CUSTOMS FOR DEPLOYMENT OF CHINA CUSTOMS CLEARANCE SYSTEM

Retrieved on: 
Thursday, July 27, 2023
General Administration of Customs, Blockchain, Philippine Health Insurance Corporation, Partnership, Tourism Infrastructure and Enterprise Zone Authority, ASEAN, Government of the Philippines, ACFTA, CDEC, Land banking, Food safety, Bureau of Internal Revenue, Average revenue per user, RCEP, Security (finance), Securities and Exchange Commission (Philippines), Blockchain-based database, Government, Philippine Government Securities, Quarantine, Ministry of Investment, Republic, National Bureau of Investigation (Philippines), Regional Comprehensive Economic Partnership, MITI, Artificial intelligence, Architecture, BOC, AI, Cardano (blockchain platform), Philippine Economic Zone Authority, Cryptocurrency, Warehouse, Customs

KUALA LUMPUR, Malaysia, July 27, 2023 /PRNewswire/ -- MY E.G. Services Berhad ("MYEG" or "the Group") has entered into a collaboration and secured regulatory approval to deploy its blockchain-based customs clearance and processing services for trade flows between the Philippines and China.

Key Points: 
  • Services Berhad ("MYEG" or "the Group") has entered into a collaboration and secured regulatory approval to deploy its blockchain-based customs clearance and processing services for trade flows between the Philippines and China.
  • TS Wong, Group Managing Director of MYEG, said: "At MYEG, we are pleased that the advantages of deploying a Web3 + AI-based solution i.e.
  • Ztrade in offering faster, secure, more intelligent and more cost-effective processing of cross-border trades are now also being recognised in the Philippines, besides in Malaysia and China.
  • Since commencing operations in 2017, the Group has gone on to establish itself as a leading provider of e-government services in the Philippines.

Colorado Parents, Community Organizations, CDHS, Illuminate Colorado and CDEC Team Members Launch Child Abuse Prevention Month at Capitol Event

Retrieved on: 
Monday, April 3, 2023
Overload, Family resource program, Colorado Department of Human Services, Molina Healthcare, Human services, Parent, CDEC, Risk, Colorado Department of Early Childhood, Organization, Child, Child abuse, KCNC-TV, CDHS, National Child Abuse Prevention Month, Caregiver, Safety, Department of Human Services, Toy, Residential care

DENVER, April 3, 2023 /PRNewswire/ -- Community partners, child advocates and representatives from the Colorado Department of Human Services (CDHS), Illuminate Colorado, and the Colorado Department of Early Childhood (CDEC) launched Child Abuse Prevention Month at a State Capitol event today. The occasion reinforced the importance of organizations, individuals and communities working together to strengthen families, one of the most effective ways to prevent child abuse and neglect.

Key Points: 
  • DENVER, April 3, 2023 /PRNewswire/ -- Community partners, child advocates and representatives from the Colorado Department of Human Services (CDHS), Illuminate Colorado, and the Colorado Department of Early Childhood (CDEC) launched Child Abuse Prevention Month at a State Capitol event today.
  • The occasion reinforced the importance of organizations, individuals and communities working together to strengthen families, one of the most effective ways to prevent child abuse and neglect.
  • The event featured speakers who reflect the continuum of child abuse prevention - from families who have accessed support, to community-based organizations that connect families to the resources they need, to the prevention work and resources provided by caseworkers and the child welfare system.
  • To learn more about child abuse and neglect prevention and activities happening around the state, visit CO4Kids.org .

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

Retrieved on: 
Wednesday, March 8, 2023
MD, BioCryst Pharmaceuticals, PARK, Health Canada, Patient, CADTH, Disease, Hereditary angioedema, FRCPC, British Society of Cinematographers, HAE, CDEC, RESEARCH, Pharmaceutical industry, Health insurance

RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for ORLADEYO® (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.

Key Points: 
  • In issuing this positive recommendation, CADTH is opening the door to many Canadian HAE patients being able to access ORLADEYO,” said Stephen Betschel, HBSc, MD, FRCPC, FAAAAI, Chair of the Canadian Hereditary Angioedema Network.
  • “BioCryst is delighted that ORLADEYO has received this positive recommendation from CADTH.
  • Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
  • The full CADTH reimbursement recommendation for ORLADEYO is available on CADTH’s website .

VABYSMO® (faricimab injection) receives positive CADTH recommendation for the treatment of Diabetic Macular Edema (DME) in adults

Retrieved on: 
Thursday, November 3, 2022
Immunoglobulin G, Planetary Missions Program Office, Reading, CNIB Foundation, Medication, Visual impairment, Prevalence, Diabetic retinopathy, Retina, Macular edema, Element, Blood, CADTH, Injection, Patient, Quality of life, McMaster University, Hindawi (publisher), Heart, Diabetes, American Journal, Diagnosis, Science, Observational study, National Eye Institute, DME, Neovascularization, Research, Review, Artificial intelligence, Eye, Roche, CDEC, Severe cognitive impairment, Infection, Swelling, Central nervous system, Vascular endothelial growth factor A, Macular degeneration, Pharmaceutical industry, Publishing, Faricimab, Ophthalmology

Roche Canada is delighted that CADTH has recognized the clinical evidence and benefit shown by VABYSMO for use in Canadians living with DME.

Key Points: 
  • Roche Canada is delighted that CADTH has recognized the clinical evidence and benefit shown by VABYSMO for use in Canadians living with DME.
  • This milestone marks the second positive recommendation for VABYSMO, following the recent recommendation from CADTH for the treatment of neovascular (wet) age-related macular degeneration in September 2022.
  • "Costs And Quality Of Life In Diabetic Macular Edema: Canadian Burden Of Diabetic Macular Edema Observational Study (C-REALITY)".Journal Of Ophthalmology, 2014.
  • "Costs And Quality Of Life In Diabetic Macular Edema: Canadian Burden Of Diabetic Macular Edema Observational Study (C-REALITY)".Journal Of Ophthalmology, 2014.

Novartis' Multiple Sclerosis Brands Mayzent and Kesimpta Both Show Strong Growth in Canada According to Surveyed Neurologists in Spherix Report

Retrieved on: 
Thursday, May 26, 2022
Physician, Diroximel fumarate, BMS, Dermatology, Ponesimod, Patient, Nephrology, Mark (given name), CDEC, Neurology, Novartis, Research, Gastroenterology, HCP, DMF, MS, Roche, Multiple sclerosis, DMT, Growth, Parallel, Pharmaceutical industry, Retail, Ozanimod, Dimethyl fumarate, EU, Biogen

EXTON, Pa., May 26, 2022 /PRNewswire/ -- Following an eventful 2021 that included the launch of two new brands—Novartis' Kesimpta and BMS' Zeposia—and generic versions of Biogen's Tecfidera, the Canadian multiple sclerosis (MS) market appears to be settling into patterns of strong uptake of new therapies.

Key Points: 
  • Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the MS market in Canada through their RealTime Dynamix: Multiple Sclerosis (Canada) service since 2019.
  • Below are a few key insights:
    Capitalizing on recent positive pCPA2 negotiations for Mayzent (October 2021) and Kesimpta (March 2022), Novartis has seen strong growth for its MS portfolio in Canada.
  • Neurologists report the greatest recognized increase in promotional efforts for these brands and the highest frequency of recent sales representative interaction.
  • The Q2 2022 report is the seventh semiannual edition included in the RealTime Dynamix: Multiple Sclerosis (Canada) service.

EMD Serono's Mavenclad and Novartis' Kesimpta Emerging as Growth Brands After Eventful 2021 for the Multiple Sclerosis Market in Canada, According to Spherix Global Insights

Retrieved on: 
Monday, December 6, 2021
Patient, Genentech, Cladribine, Neurology, Time, Nephrology, Mark (given name), BMS, DMT, Novartis, MS, Multiple sclerosis, Awareness, DMTS, Dermatology, TG, Health Canada, Merck Serono, Physician, Ublituximab, PCPA, Biogen, RRMS, Research, Parallel, HCP, SPMS, CDEC, Therapy, Gastroenterology, RMS, Fatigue, DMF, Health insurance, Pharmaceutical industry, Generic drug, Retail

Insights uncovered shifts in physicians' perceptions and self-reported prescribing patterns across disease-modifying therapy (DMT) brands (and implications within drug classes) driven by these market events.

Key Points: 
  • Insights uncovered shifts in physicians' perceptions and self-reported prescribing patterns across disease-modifying therapy (DMT) brands (and implications within drug classes) driven by these market events.
  • The dynamics in Canada will unfold quite differently, as generics entered the market while Vumerity is still under Health Canada review.
  • New prescription share patterns suggest that Genentech's Ocrevus, Kesimpta, and EMD Serono's Mavenclad will experience some of the strongest near-term growth.
  • Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.

Perfect World embraces new changes in digital entertainment industry with sci-tech and culture

Retrieved on: 
Monday, August 2, 2021
Cities in China, East China, Jiangnan, Shanghai, Wu, Yangtze River Delta, Administrative divisions

SHANGHAI, Aug. 2, 2021 /PRNewswire/ -- Perfect World CEO Dr. Robert H. Xiao attended and addressed the China Digital Entertainment Congress (CDEC) in Shanghai on July 29.

Key Points: 
  • SHANGHAI, Aug. 2, 2021 /PRNewswire/ -- Perfect World CEO Dr. Robert H. Xiao attended and addressed the China Digital Entertainment Congress (CDEC) in Shanghai on July 29.
  • In his speech, Dr. Xiao explained how Perfect World explores new product forms under the support of scientific technology and culture.
  • Additionally, Perfect World is actively applying cutting-edge technologies into its cultural products aiming at providing users brand-new scenes and experiences.
  • "Traditional Chinese culture has always been a source of inspiration for Perfect World.